凝血酶原片段1+2在心血管疾病中的作用
|
摘要
凝血酶原片段1+2(F1+2)是凝血酶原酶复合物激活凝血酶原的过程中从凝血酶原上解离出的多肽片段。近年来研究显示,F1+2浓度升高与多种心血管危险因素相关。进一步研究表明F1+2与心血管疾病,如急性冠状动脉综合征、心房颤动、静脉血栓形成、卒中等有密切的联系,并且对血栓形成疾病的诊断、预后的评估有一定潜在价值。
Prothrombin fragment 1 + 2(F1 + 2) comes from cleavage of prothrombin. Elevated F1 + 2has been found in relation to the presence of cardiovascular disease risk factors. Increased F1 + 2 levels have been reported in acute coronary syndromes,atrial fibrillation,venous thromboembolism,and stroke.Further more,elevated F1 + 2 shows potential diagnostic and prognostic value in thrombosis disease.
Prothrombin fragment 1 + 2(F1 + 2) comes from cleavage of prothrombin. Elevated F1 + 2has been found in relation to the presence of cardiovascular disease risk factors. Increased F1 + 2 levels have been reported in acute coronary syndromes,atrial fibrillation,venous thromboembolism,and stroke.Further more,elevated F1 + 2 shows potential diagnostic and prognostic value in thrombosis disease.
引文
[1]Lloyd-Jones D,Adams R,Carnethon M,et al.Heart disease and stroke statistics-2009 update:a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee[J].Circulation,2009,119(3):480-486.
[2]Baglin T.Venous thromboembolism in hospitalised patients:a public health crisis?[J].Br J Haematol,2008,141(6):764-770.
[3]Folsom AR.Hemostatic risk factors for atherothrombotic disease:an epidemiologic view[J].Thromb Haemost,2001,86(1):366-373.
[4]Tracy RP.Thrombin,inflammation,and cardiovascular disease:an epidemiologic perspective[J].Chest,2003,124(3 Suppl):49S-57S.
[5]Libby P,Theroux P.Pathophysiology of coronary artery disease[J].Circulation,2005,111(25):3481-3488.
[6]Kannel WB.Overview of hemostatic factors involved in atherosclerotic cardiovascular disease[J].Lipids,2005,40(12):1215-1220.
[7]Shah PK.Thrombogenic risk factors for atherothrombosis[J].Rev Cardiovasc Med,2006,7(1):10-16.
[8]Chan MY,Andreotti F,Becker RC.Hypercoagulable states in cardiovascular disease[J].Circulation,2008,118(22):2286-2297.
[9]Stegnar M,Vene N,Bozic M.Do haemostasis activation markers that predict cardiovascular disease exist?[J].Pathophysiol Haemost Thromb,2003,33(5/6):302-308.
[10]Bauer KA.Laboratory markers of coagulation activation[J].Arch Pathol Lab Med,1993,117(1):71-77.
[11]Dielis AW,Castoldi E,Spronk HM,et al.Coagulation factors and the protein C system as determinants of thrombin generation in a normal population[J].J Thromb Haemost,2008,6(1):125-131.
[12]Musial J,Pajak A,Undas A,et al.Thrombin generation markers and coronary heart disease risk factors in a Polish population sample[J].Thromb Haemost,1997,77(4):697-700.
[13]Lowe GD.Can haematological tests predict cardiovascular risk?The 2005 Kettle Lecture[J].Br J Haematol,2006,133(3):232-250.
[14]Lowe GD.Inflammatory/hemostatic biomarkers and cardiovascular risk:coming of age?[J].J Thromb Haemost,2007,5(6):1125-1127.
[15]Paramo JA,Orbe J,Beloqui O,et al.Prothrombin fragment 1+2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease[J].Stroke,2004,35(5):1085-1089.
[16]Metcalf PA,Folsom AR,Davis CE,et al.Haemostasis and carotid artery wall thickness in non-insulin dependent diabetes mellitus[J].Diabetes Res Clin Pract,2000,47(1):25-35.
[17]Kienast J,Thompson SG,Raskino C,et al.Prothrombin activation fragment 1+2 and thrombin antithrombin III complexes in patients with angina pectoris:relation to the presence and severity of coronary atherosclerosis[J].Thromb Haemost,1993,70(4):550-553.
[18]Lowe GD,Rumley A,Sweetnam PM,et al.Fibrin D-dimer,markers of coagulation activation and the risk of major ischaemic heart disease in the caerphilly study[J].Thromb Haemost,2001,86(3):822-827.
[19]Folsom AR,Aleksic N,Park E,et al.Prospective study of fibrinolytic factors and incident coronary heart disease:the atherosclerosis risk in communities(ARIC)study[J].Arterioscler Thromb Vasc Biol,2001,21(4):611-617.
[20]Tzoulaki I,Murray GD,Price JF,et al.Hemostatic factors,inflammatory markers,and progressive peripheral atherosclerosis:the edinburgh artery study[J].Am J Epidemiol,2006,163(4):334-341.
[21]Pawlak K,Mysliwiec M,Pawlak D.Haemostatic system,biochemical profiles,kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients[J].Thromb Res,2010,125(2):e40-e45.
[22]Orbe J,Zudaire M,Serrano R,et al.Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test[J].Thromb Haemost,2008,99(2):382-387.
[23]Granger CB,Becker R,Tracy RP,et al.Thrombin generation,inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin:results from the GUSTO-I Trial.GUSTO-I Hemostasis Substudy Group.Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries[J].J Am Coll Cardiol,1998,31(3):497-505.
[24]Elmas E,Kaelsch T,Wolpert C,et al.Assessment of markers of thrombin generation in patients with acute myocardial infarction complicated by ventricular fibrillation[J].Clin Cardiol,2006,29(4):165-169.
[25]周自强,胡大一,陈捷,等.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494.
[26]Watson T,Shantsila E,Lip GY.Mechanisms of thrombogenesis in atrial fibrillation:Virchow's triad revisited[J].Lancet,2009,373(9658):155-166.
[27]Koefoed B G,Feddersen C,Gullov AL,et al.Effect of fixed minidose warfarin,conventional dose warfarin and aspirin on INR and prothrombin fragment 1+2 in patients with atrial fibrillation[J].Thromb Haemost,1997,77(5):845-848.
[28]Ohara K,Inoue H,Nozawa T,et al.Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation[J].Int J Cardiol,2008,126(3):316-321.
[29]Furie KL,Rosenberg R,Thompson JL,et al.Thrombin generation in non-cardioembolic stroke subtypes:the hemostatic system activation study[J].Neurology,2004,63(5):777-784.
[30]O'Donnell MJ,Berge E,Sandset PM.Are there patients with acute ischemic stroke and atrial fibrillation that benefit from low molecular weight heparin?[J].Stroke,2006,37(2):452-455.
[31]Haapaniemi E,Soinne L,Syrjala M,et al.Serial changes in fibrinolysis and coagulation activation markers in acute and convalescent phase of ischemic stroke[J].Acta Neurol Scand,2004,110(4):242-247.
[32]Di Tullio MR,Homma S,Jin Z,et al.Aortic atherosclerosis,hypercoagulability,and stroke the APRIS(Aortic Plaque and Risk of Ischemic Stroke)study[J].J Am Coll Cardiol,2008,52(10):855-861.
[33]Meng R,Ji X,Li B,et al.Dynamical levels of plasma F(1+2)and D-dimer in patients with acute cerebral infarction during intravenous urokinase thrombolysis[J].Neurol Res,2009,31(4):367-370.
[34]Poli D,Antonucci E,Cecchi E,et al.Clotting activation after oral anticoagulant therapy discontinuation:a risk factor for recurrent venous thromboembolism[J].Blood Coagul Fibrinolysis,2004,15(3):221-225.
[35]Ay C,Vormittag R,Dunkler D,et al.D-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer:results from the Vienna Cancer and Thrombosis Study[J].J Clin Oncol,2009,27(25):4124-4129.
[36]Ota S,Wada H,Abe Y,et al.Elevated levels of prothrombin fragment 1+2 indicate high risk of thrombosis[J].Clin Appl Thromb Hemost,2008,14(3):279-285.
[37]Wexels F,Haslund A,Dahl OE,et al.Thrombin split products(prothrombin fragment 1+2)in urine in patients with suspected deep vein thrombosis admitted for radiological verification[J].Thromb Res,2013,131(6):560-563.
[2]Baglin T.Venous thromboembolism in hospitalised patients:a public health crisis?[J].Br J Haematol,2008,141(6):764-770.
[3]Folsom AR.Hemostatic risk factors for atherothrombotic disease:an epidemiologic view[J].Thromb Haemost,2001,86(1):366-373.
[4]Tracy RP.Thrombin,inflammation,and cardiovascular disease:an epidemiologic perspective[J].Chest,2003,124(3 Suppl):49S-57S.
[5]Libby P,Theroux P.Pathophysiology of coronary artery disease[J].Circulation,2005,111(25):3481-3488.
[6]Kannel WB.Overview of hemostatic factors involved in atherosclerotic cardiovascular disease[J].Lipids,2005,40(12):1215-1220.
[7]Shah PK.Thrombogenic risk factors for atherothrombosis[J].Rev Cardiovasc Med,2006,7(1):10-16.
[8]Chan MY,Andreotti F,Becker RC.Hypercoagulable states in cardiovascular disease[J].Circulation,2008,118(22):2286-2297.
[9]Stegnar M,Vene N,Bozic M.Do haemostasis activation markers that predict cardiovascular disease exist?[J].Pathophysiol Haemost Thromb,2003,33(5/6):302-308.
[10]Bauer KA.Laboratory markers of coagulation activation[J].Arch Pathol Lab Med,1993,117(1):71-77.
[11]Dielis AW,Castoldi E,Spronk HM,et al.Coagulation factors and the protein C system as determinants of thrombin generation in a normal population[J].J Thromb Haemost,2008,6(1):125-131.
[12]Musial J,Pajak A,Undas A,et al.Thrombin generation markers and coronary heart disease risk factors in a Polish population sample[J].Thromb Haemost,1997,77(4):697-700.
[13]Lowe GD.Can haematological tests predict cardiovascular risk?The 2005 Kettle Lecture[J].Br J Haematol,2006,133(3):232-250.
[14]Lowe GD.Inflammatory/hemostatic biomarkers and cardiovascular risk:coming of age?[J].J Thromb Haemost,2007,5(6):1125-1127.
[15]Paramo JA,Orbe J,Beloqui O,et al.Prothrombin fragment 1+2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease[J].Stroke,2004,35(5):1085-1089.
[16]Metcalf PA,Folsom AR,Davis CE,et al.Haemostasis and carotid artery wall thickness in non-insulin dependent diabetes mellitus[J].Diabetes Res Clin Pract,2000,47(1):25-35.
[17]Kienast J,Thompson SG,Raskino C,et al.Prothrombin activation fragment 1+2 and thrombin antithrombin III complexes in patients with angina pectoris:relation to the presence and severity of coronary atherosclerosis[J].Thromb Haemost,1993,70(4):550-553.
[18]Lowe GD,Rumley A,Sweetnam PM,et al.Fibrin D-dimer,markers of coagulation activation and the risk of major ischaemic heart disease in the caerphilly study[J].Thromb Haemost,2001,86(3):822-827.
[19]Folsom AR,Aleksic N,Park E,et al.Prospective study of fibrinolytic factors and incident coronary heart disease:the atherosclerosis risk in communities(ARIC)study[J].Arterioscler Thromb Vasc Biol,2001,21(4):611-617.
[20]Tzoulaki I,Murray GD,Price JF,et al.Hemostatic factors,inflammatory markers,and progressive peripheral atherosclerosis:the edinburgh artery study[J].Am J Epidemiol,2006,163(4):334-341.
[21]Pawlak K,Mysliwiec M,Pawlak D.Haemostatic system,biochemical profiles,kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients[J].Thromb Res,2010,125(2):e40-e45.
[22]Orbe J,Zudaire M,Serrano R,et al.Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test[J].Thromb Haemost,2008,99(2):382-387.
[23]Granger CB,Becker R,Tracy RP,et al.Thrombin generation,inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin:results from the GUSTO-I Trial.GUSTO-I Hemostasis Substudy Group.Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries[J].J Am Coll Cardiol,1998,31(3):497-505.
[24]Elmas E,Kaelsch T,Wolpert C,et al.Assessment of markers of thrombin generation in patients with acute myocardial infarction complicated by ventricular fibrillation[J].Clin Cardiol,2006,29(4):165-169.
[25]周自强,胡大一,陈捷,等.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494.
[26]Watson T,Shantsila E,Lip GY.Mechanisms of thrombogenesis in atrial fibrillation:Virchow's triad revisited[J].Lancet,2009,373(9658):155-166.
[27]Koefoed B G,Feddersen C,Gullov AL,et al.Effect of fixed minidose warfarin,conventional dose warfarin and aspirin on INR and prothrombin fragment 1+2 in patients with atrial fibrillation[J].Thromb Haemost,1997,77(5):845-848.
[28]Ohara K,Inoue H,Nozawa T,et al.Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation[J].Int J Cardiol,2008,126(3):316-321.
[29]Furie KL,Rosenberg R,Thompson JL,et al.Thrombin generation in non-cardioembolic stroke subtypes:the hemostatic system activation study[J].Neurology,2004,63(5):777-784.
[30]O'Donnell MJ,Berge E,Sandset PM.Are there patients with acute ischemic stroke and atrial fibrillation that benefit from low molecular weight heparin?[J].Stroke,2006,37(2):452-455.
[31]Haapaniemi E,Soinne L,Syrjala M,et al.Serial changes in fibrinolysis and coagulation activation markers in acute and convalescent phase of ischemic stroke[J].Acta Neurol Scand,2004,110(4):242-247.
[32]Di Tullio MR,Homma S,Jin Z,et al.Aortic atherosclerosis,hypercoagulability,and stroke the APRIS(Aortic Plaque and Risk of Ischemic Stroke)study[J].J Am Coll Cardiol,2008,52(10):855-861.
[33]Meng R,Ji X,Li B,et al.Dynamical levels of plasma F(1+2)and D-dimer in patients with acute cerebral infarction during intravenous urokinase thrombolysis[J].Neurol Res,2009,31(4):367-370.
[34]Poli D,Antonucci E,Cecchi E,et al.Clotting activation after oral anticoagulant therapy discontinuation:a risk factor for recurrent venous thromboembolism[J].Blood Coagul Fibrinolysis,2004,15(3):221-225.
[35]Ay C,Vormittag R,Dunkler D,et al.D-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer:results from the Vienna Cancer and Thrombosis Study[J].J Clin Oncol,2009,27(25):4124-4129.
[36]Ota S,Wada H,Abe Y,et al.Elevated levels of prothrombin fragment 1+2 indicate high risk of thrombosis[J].Clin Appl Thromb Hemost,2008,14(3):279-285.
[37]Wexels F,Haslund A,Dahl OE,et al.Thrombin split products(prothrombin fragment 1+2)in urine in patients with suspected deep vein thrombosis admitted for radiological verification[J].Thromb Res,2013,131(6):560-563.